Skip to main content
. 2021 Oct 12;11:725336. doi: 10.3389/fonc.2021.725336

Figure 2.

Figure 2

Runx3 knockdown inhibits acute myeloid leukemia (AML) progression in vivo. (A) Experimental scheme for investigating RUNX3 role in AML progression in vivo. (B) qRT-PCR analysis showing Runx3 knockdown in sorted AML cells from bone marrow of scramble control (Vector) and Runx3 knockdown (Runx3 KD) AML mice at day 45 posttransplantation. Each dot represents a mouse. (C) Western blot analysis showing RUNX3 knockdown. (D) Representative cytometric flow plots (left) and statistic results (right) show that Runx3 knockdown decreases leukemia burden in peripheral blood (PB) at day 28 posttransplantation (n = 5 mice). (E) The percentage of green fluorescent protein (GFP)+ AML cells in the PB at day 45 posttransplantation (n = 5 mice). (F) Representative cytometric flow plots (left), the percentage of GFP+ AML cells (middle), and the number of GFP+ leukemic cells (right) in bone marrow (BM) at day 45 posttransplantation (n = 5 mice). (G) Representative image of spleen (upper left), liver (bottom left), and quantitative analysis of spleen weight (middle) and liver weight (right) from scramble control and Runx3 knockdown AML mice (n = 5 mice). (H) Wright–Giemsa staining of blood smear and H&E staining of spleen and liver from scramble control and Runx3 knockdown AML mice. Scale bar: blood smear 20 µm, spleen 300 µm, liver 100 µm. (I) Survival analysis of mice transplanted with scramble control or Runx3 knockdown AML cells. Data shown are combined from two independent transplants. (n = 5 mice). p = 0.0374, log-rank test.